香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2172） 授出購股權 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第17.06A條 而作出。 微創腦科學有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈，於二零二五年八月二十八日，本公司已決議根據本公 司於二零二三年七月十二日採納之股份計劃（「股份計劃」）向63名合資格參與 者（「承授人」）授出購股權（「購股權」），以合共認購最多402,300股本公司股本 中每股面值0.00002美元之本公司普通股（「股份」），惟須待承授人接納後，方可 作實。 有關購股權之詳情載列如下： – 1 – 授出日期 二零二五年八月二十八日（「授出日期」） 承授人之數目 63名承授人（全部承授人均 ...

Core Viewpoint - Micron Brain Science (02172) experienced a decline of over 5%, with a current price of HKD 13.05 and a trading volume of HKD 77.84 million [1] Financial Performance - For the first half of 2025, the company reported revenue of approximately HKD 383 million, a year-on-year decrease of 6.2% [1] - The profit attributable to equity shareholders was HKD 92.923 million, reflecting a year-on-year decline of 35.25% [1] - The interim dividend was set at HKD 0.05 per share, down from HKD 0.08 per share in the same period last year [1] International Business Growth - The company's international business continued to show strong growth, with overseas revenue reaching HKD 47.1 million, an increase of 67.4% compared to the same period last year [1] - Profit from the international business segment experienced rapid growth [1] - Sales revenue in the Asia-Pacific, Europe, Middle East and Africa (EMEA), North America, and Latin America regions all achieved varying degrees of rapid growth [1]

Core Viewpoint - Micron Brain Science (02172) experienced a decline of over 5%, with a current price of HKD 13.05 and a trading volume of HKD 77.84 million [1] Financial Performance - For the first half of 2025, the company reported revenue of approximately HKD 383 million, a year-on-year decrease of 6.2% [1] - The profit attributable to equity shareholders was HKD 92.923 million, reflecting a year-on-year decrease of 35.25% [1] - The interim dividend was set at HKD 0.05 per share, down from HKD 0.08 per share in the same period last year [1] International Business Growth - The company's international business continued to show strong growth, with overseas revenue reaching HKD 47.1 million, a year-on-year increase of 67.4% [1] - Profit from the international business segment experienced rapid growth [1] - Sales revenue in the Asia-Pacific, Europe, Middle East and Africa (EMEA), North America, and Latin America regions all achieved varying degrees of rapid growth [1]

Core Insights - Micron Brain Science (02172) reported a mid-year performance for 2025, with revenue approximately 383 million yuan, a year-on-year decrease of 6.2% [1] - The company's profit attributable to equity shareholders was 92.923 million yuan, down 35.25% year-on-year, with earnings per share at 0.16 yuan [1] International Business Performance - The international business segment continued to show strong growth, with overseas revenue reaching 47.1 million yuan, an increase of 67.4% compared to the same period last year [1] - Profits from the international business division experienced rapid growth, indicating a successful expansion strategy [1] Product and Market Expansion - As of the end of the reporting period, the company had eight products launched internationally, achieving commercialization in 34 overseas countries or regions [1] - The products cover nine countries that rank among the top ten globally in terms of neurosurgical procedures, highlighting the company's competitive positioning [1] - The company secured nine product registration certificates in various overseas markets, laying a solid foundation for scaling up international revenue [1]

Core Viewpoint - MicroPort NeuroTech (02172.HK) reported a revenue of RMB 382.9 million for the six months ending June 30, 2025, a decrease of 6.2% compared to RMB 408.2 million for the same period in 2024, primarily due to various factors affecting product sales and market dynamics [1] Revenue Breakdown - The revenue is mainly derived from hemorrhagic stroke products, carotid artery atherosclerosis products, and acute ischemic stroke products [1] - The overseas business continued to show strong growth, with revenue increasing approximately 67.4% year-on-year, and sales in the Asia-Pacific, North America, Latin America, and Europe, Middle East, and Africa regions all experienced varying degrees of rapid growth [1] - Revenue from hemorrhagic stroke products, including the spring coil series and the globally unique WILLIS intracranial covered stent, maintained rapid growth, while the market share of spring coils increased [1] - Revenue from carotid artery atherosclerosis products declined mainly due to the cessation of cooperation with original agents and the impact of centralized procurement in certain regions [1] Profitability Metrics - The company's gross profit margin was 73.4%, an increase of 1.1 percentage points from 72.3% in the same period last year, attributed to improved production efficiency [1] - The net profit recorded during the reporting period was approximately RMB 92.7 million [1] Dividend Announcement - The board of directors proposed an interim dividend of HKD 0.05 per ordinary share for the six months ending June 30, 2025 [1]

Core Viewpoint - MicroPort NeuroTech (02172) reported a decline in revenue and profit for the first half of 2025, despite strong growth in international business [1] Financial Performance - Revenue for the period was approximately 383 million yuan, a year-on-year decrease of 6.2% [1] - Profit attributable to equity shareholders was 92.923 million yuan, down 35.25% year-on-year [1] - Earnings per share stood at 0.16 yuan [1] International Business Growth - The company's international business continued to show strong growth, with overseas revenue reaching 47.1 million yuan, an increase of 67.4% compared to the same period last year [1] - Profits from the international business segment experienced rapid growth [1] - Sales revenue in the Asia-Pacific, Europe, Middle East and Africa (EMEA), North America, and Latin America regions all saw varying degrees of rapid growth [1] Product Expansion - As of the end of the reporting period, the company had 8 products launched internationally, achieving commercialization in 34 overseas countries or regions [1] - The products cover 9 countries that rank among the top ten globally in terms of neuro-interventional procedures [1] - The company secured 9 product registrations in different overseas countries or regions, laying a solid foundation for scaling up overseas revenue [1]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，執行董事為謝志永先生及王亦群先生；非執行董事為常兆華博士、孫慶蔚先生及吳夏女士；及獨立非執行董事為張 海曉博士、樊欣先生及李志勇先生。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 微創腦科學有限公司 | | 股份代號 | 02172 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月的中期股息 | | 公告日期 | 2025年8月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroPort NeuroScientic Corporation 微創腦科學有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2172） 截至2025年6月30日止六個月之 未經審核中期業績公告 本公司董事會欣然公佈本集團截至2025年6月30日止六個月（「報告期內」）的未 經審核綜合業績，連同截至2024年6月30日止六個月（「上年同期」）未經審核的 比較數字，其已由審核委員會審閱。 於截至2025年6月30日止六個月，本集團的收入主要來自出血性腦卒中產品、 腦動脈粥樣硬化狹窄產品以及急性缺血性腦卒中產品。 報告期內，本集團錄得收入約人民幣382.9百萬元，其中： 報告期內，本集團錄得淨溢利約人民幣92.7百萬元。董事會決議建議派發截至 2025年6月30日止六個月之中期股息每股普通股0.05港元。 – 1 – (1) 本集團海外業務延續強勁增長態勢，報告期內 ...

微创脑科学(02172)发布公告，于2025年8月22日，根据有关2024末期股息的以股代息计划发行42.48万代 息股份。 ...

智通财经APP讯，微创脑科学(02172)发布公告，于2025年8月22日，根据有关2024末期股息的以股代息 计划发行42.48万代息股份。 ...